Your browser doesn't support javascript.
Treatment of Opioid Use Disorder With Buprenorphine Among US Adolescents and Young Adults During the Early COVID-19 Pandemic.
Alinsky, Rachel H; Prichett, Laura; Chang, Hsien-Yen; Alexander, G Caleb; Stein, Bradley D; Saloner, Brendan.
  • Alinsky RH; Division of Adolescent/Young Adult Medicine, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Maryland. Electronic address: RAlinsk1@jhmi.edu.
  • Prichett L; Department of Pediatrics, Epidemiology and Data Management (BEAD) Core, Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Chang HY; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Alexander GC; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Stein BD; RAND Corporation, Pittsburgh Office, Pittsburgh, Pennsylvania.
  • Saloner B; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
J Adolesc Health ; 71(2): 239-241, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1930929
ABSTRACT

PURPOSE:

The COVID-19 pandemic's impact on buprenorphine treatment for opioid use disorder among adolescents and young adults (AYAs) is unknown.

METHODS:

We used IQVIA Longitudinal Prescription Claims, including US AYAs aged 12-29 with at least 1 buprenorphine fill between January 2018 and August 2020, stratifying by age group and insurance. We compared buprenorphine prescriptions in March-August 2019 to March-August 2020.

RESULTS:

The monthly buprenorphine prescription rate increased 8.3% among AYAs aged 12-17 but decreased 7.5% among 18- to 24-year-olds and decreased 5.1% among 25- to 29-year-olds. In these age groups, Medicaid prescriptions did not significantly change, whereas commercial insurance prescriptions decreased 12.9% among 18- to 24-year-olds and 11.8% in 25- to 29-year-olds, and cash/other prescriptions decreased 18.7% among 18- to 24-year-olds and 19.9% in 25- to 29-year-olds (p < .001 for all).

DISCUSSION:

Buprenorphine prescriptions paid with commercial insurance or cash among young adults significantly decreased early in the pandemic, suggesting a possible unmet treatment need among this group.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Buprenorphine / COVID-19 / Opioid-Related Disorders Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Humans / Young adult Country/Region as subject: North America Language: English Journal: J Adolesc Health Journal subject: Pediatrics Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Buprenorphine / COVID-19 / Opioid-Related Disorders Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Humans / Young adult Country/Region as subject: North America Language: English Journal: J Adolesc Health Journal subject: Pediatrics Year: 2022 Document Type: Article